PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned
Conversations with CEI20 Nov 2025

PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

On June 18, 2025, the FDA approved Yeztugo, the brand name for subcutaneous lenacapavir, a prescription medication used for the pre-exposure prophylaxis of HIV. Subcutaneous lenacapavir is administered twice a year (every six months) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at risk. With patients only needing lenacapavir twice a year for HIV prevention, the field has been optimistic about the potential for lenacapavir to reduce barriers and improve access to PrEP. Since we are still early in the rollout subcutaneous lenacapavir, many providers have questions about how to offer it to their patients—from workflow to billing to managing potential side effects and drug-drug interactions.

On this episode, Antonio Urbina, MD, Medical Director for CEI’s HIV Primary Care and Prevention Center of Excellence, speaks with Alex Danforth, PharmD. Alex Danforth is a clinical pharmacist in Rochester, NY. She practices at Trillium Health, a federally qualified health center, where she works with patients and providers to help manage medications and optimize care. Alex currently provides clinical leadership for HIV treatment and prevention programs.

Drs. Urbina and Danforth talk about the latest New York State Clinical Guidelines for PrEP, which were updated on October 16th. The new guidelines provide important updates, including subcutaneous lenacapavir. They discuss important considerations for initiating patients on lenacapavir as well as some early lessons learned from implementing lenacapavir in their Rochester- and New York City-based clinics. Related Content:

Episoder(60)

Highlights and Perspectives from the 11th Annual NYS Sexual Health Conference

Highlights and Perspectives from the 11th Annual NYS Sexual Health Conference

Live from Canandaigua…it’s the 11th Annual NYS Sexual Health Conference! The CEI Sexual Health Center of Excellence hosted the 11th Annual NYS Sexual Health Conference in-person on Friday May 2, 2025,...

10 Jul 202516min

Xylazine & Medetomidine & Nitazines, Oh My! An Update on New York State’s Drug Supply

Xylazine & Medetomidine & Nitazines, Oh My! An Update on New York State’s Drug Supply

New York drug overdose deaths and death rates are on the decline, but with significant disparities and the current, toxic drug supply is partially to blame. Harmful additives like fentanyl analogues, ...

12 Jun 202529min

CEI…we got you! Evolving with the Science

CEI…we got you! Evolving with the Science

In this episode of Conversations with CEI, we engage with CEI’s clinicians, researchers, and public health experts to explore current and emerging issues in HIV primary care, sexual health, Hepatitis ...

16 Mai 202538min

Navigating Measles Vaccine Recommendations for Patients with HIV

Navigating Measles Vaccine Recommendations for Patients with HIV

In light of the increase in measles cases within the United States, this episode features Dr. Steven Fine, an infectious disease expert, who offers a comprehensive exploration of the history and progr...

8 Mai 202520min

The Invisible Latino HIV Crisis

The Invisible Latino HIV Crisis

In May 2024, the Centers for Disease Control and Prevention (CDC) released its annual HIV surveillance reports. The new data show a continuation of year-over-year reductions through 2022 in the estima...

10 Apr 202521min

Updates in Syphilis: Looking Back to Look Forward

Updates in Syphilis: Looking Back to Look Forward

Let’s dive in! This month, we welcome new hosts Patrick Passarelli, MD, an infectious diseases fellow at the University of Rochester, and Nicholas Gerbino, a public health professional at the Monroe C...

13 Mar 202534min

The Role of Opioid Treatment Programs in Hepatitis C Care: A Path to Elimination

The Role of Opioid Treatment Programs in Hepatitis C Care: A Path to Elimination

Between 2010 and 2022 (the latest year for which data are available), 194,375 New Yorkers were diagnosed with hepatitis C (HCV) and of those, 53% (103,213 individuals) are known to have cleared their ...

13 Feb 202520min

Use of Injectable Cabotegravir for HIV PrEP in Pregnancy

Use of Injectable Cabotegravir for HIV PrEP in Pregnancy

This podcast outlines some of the data presented at the 25th International AIDS Conference from HPTN 084 as it pertains to using injectable cabotegravir for HIV PrEP during pregnancy. Related Content:...

9 Jan 20259min

Populært innen Fakta

fastlegen
dine-penger-pengeradet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
treningspodden
foreldreradet
rss-strid-de-norske-borgerkrigene
rss-sunn-okonomi
jakt-og-fiskepodden
sinnsyn
takk-og-lov-med-anine-kierulf
rss-kunsten-a-leve
gravid-uke-for-uke
merry-quizmas
hverdagspsyken
hagespiren-podcast
smart-forklart
rss-kull
fryktlos
lederskap-nhhs-podkast-om-ledelse
hr-podden-2